Polarean Imaging Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Chris Von Jako

İcra Kurulu Başkanı

US$617.8k

Toplam tazminat

CEO maaş yüzdesi	38.9%
CEO görev süresi	1.4yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

We Think Shareholders Will Probably Be Generous With Polarean Imaging plc's (LON:POLX) CEO Compensation

Jul 07

Here's Why We're Watching Polarean Imaging's (LON:POLX) Cash Burn Situation

Jun 07

Insider Buying: The Polarean Imaging plc (LON:POLX) Independent Chairman Just Bought 6.6% More Shares

Mar 18

Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans

Mar 09

Polarean Imaging (LON:POLX) Shareholders Have Enjoyed An Impressive 135% Share Price Gain

Feb 01

Should You Take Comfort From Insider Transactions At Polarean Imaging plc (LON:POLX)?

Dec 28

What Type Of Shareholders Own The Most Number of Polarean Imaging plc (LON:POLX) Shares?

Nov 30

CEO Tazminat Analizi

Chris Von Jako'un ücretlendirmesi Polarean Imaging'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$618k	US$240k	-US$12m

Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 617.83K ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 356.31K ).

Tazminat ve Kazançlar: Chris şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Chris Von Jako (54 yo)

1.4yrs

Görev süresi

US$617,828

Tazminat

Dr. Christopher Richard Von Jako, also known as Chris, Ph D., serves as Chief Executive Officer and Director of Polarean Imaging plc since June 20, 2023. He serves as Board Member of nView Medical Inc. Dr....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kenneth West	Chairman of the Board	7.5yrs	US$107.55k	0.27% £ 50.8k
Christopher Von Jako	CEO & Director	1.4yrs	US$617.83k	Veri yok
Bastiaan Driehuys	Founder	less than a year	US$74.05k	1.03% £ 192.4k
Charles Osborne	CFO & Director	5.6yrs	US$443.90k	Veri yok
Neil Wadehra	Vice President of Operations	no data	Veri yok	Veri yok
Alex Dusek	Chief Commercial Officer	2.8yrs	Veri yok	Veri yok
Chase Hall	Chief Medical Advisor	less than a year	Veri yok	Veri yok
Stephen Austin	Company Secretary	6.7yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim: POLX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kenneth West	Chairman of the Board	7.5yrs	US$107.55k	0.27% £ 50.8k
Christopher Von Jako	CEO & Director	1.4yrs	US$617.83k	Veri yok
Bastiaan Driehuys	Founder	7.5yrs	US$74.05k	1.03% £ 192.4k
Charles Osborne	CFO & Director	3.8yrs	US$443.90k	Veri yok
Frank Schulkes	Non-Executive Director	2.6yrs	US$118.63k	Veri yok
Cyrille Petit	Non-Executive Director	4.4yrs	US$90.15k	0.048% £ 9.1k
Juergen Laucht	Non-Executive Director	7.5yrs	US$79.05k	Veri yok
Daniel Brague	Independent Non-Executive Director	2.5yrs	US$114.04k	Veri yok

4.1yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: POLX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Polarean Imaging Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Polarean Imaging plc Appoints Chase Hall, M.D., as Chief Medical Advisor

Bastiaan Driehuys Steps Down from His Position on the Board of Polarean Imaging plc

Polarean Imaging plc, Annual General Meeting, Jul 24, 2024

Polarean Imaging plc Announces CEO Changes

Polarean Imaging plc, Annual General Meeting, Jun 28, 2023

Less than half of directors are independent

Recent updates

Polarean Imaging plc Receives 510(K) Clearance from the U.S. Food and Drug Administration for the Specialised MRI Chest Coil

Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans

Polarean Imaging plc Appoints Chase Hall, M.D., as Chief Medical Advisor

Polarean Imaging plc to Report First Half, 2024 Results on Sep 04, 2024

Bastiaan Driehuys Steps Down from His Position on the Board of Polarean Imaging plc

Polarean Imaging plc Submits New Drug Application Supplement to the US Food and Drug Administration

Full year 2023 earnings released: US$0.055 loss per share (vs US$0.066 loss in FY 2022)

Polarean Imaging plc, Annual General Meeting, Jul 24, 2024

New major risk - Shareholder dilution

New minor risk - Financial data availability

Here's Why Polarean Imaging (LON:POLX) Must Use Its Cash Wisely

First half 2023 earnings released: US$0.035 loss per share (vs US$0.033 loss in 1H 2022)

Is Polarean Imaging (LON:POLX) In A Good Position To Invest In Growth?

Polarean Imaging plc to Report First Half, 2023 Results on Sep 07, 2023

Polarean Imaging plc to Report First Half, 2023 Results on Sep 07, 2023

New major risk - Share price stability

Polarean Receives Clearance for New MRI Chest Coil

Polarean Imaging plc Announces CEO Changes

Full year 2022 earnings released: US$0.066 loss per share (vs US$0.071 loss in FY 2021)

Polarean Imaging plc, Annual General Meeting, Jun 28, 2023

Polarean Imaging plc Announces First Clinical Scan Using XENOVIEW Conducted At Cincinnati Children’s Hospital Medical Center

Is Polarean Imaging (LON:POLX) In A Good Position To Invest In Growth?

Polarean Imaging plc Announces FDA Grants New Chemical Entity Designation for XENOVIEW

Polarean Imaging plc Announces U.S. Food and Drug Administration Grants Approval for its Drug Device Combination Product, XENOVIEW

Less than half of directors are independent

We're Keeping An Eye On Polarean Imaging's (LON:POLX) Cash Burn Rate

Polarean Imaging plc Announces Update on New Drug Application

First half 2022 earnings released: US$0.033 loss per share (vs US$0.026 loss in 1H 2021)

Polarean Imaging plc Appoints Marcella Ruddy as A Non-Executive Director

Polarean Imaging plc, Annual General Meeting, Jun 29, 2022

Full year 2021 earnings released: US$0.071 loss per share (vs US$0.044 loss in FY 2020)

Polarean Imaging plc to Report Fiscal Year 2021 Results on May 18, 2022

Polarean Imaging plc Announces Board and Committee Changes

Less than half of directors are independent

Polarean Imaging plc Announces New Drug Application Resubmission Update

Polarean Imaging plc Appoints Frank Maria Schulkes as Non-Executive Director

Polarean Imaging plc Announces Resubmission of New Drug Application

Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans

Independent Chairman recently bought UK£80k worth of stock

First half 2021 earnings released: US$0.026 loss per share (vs US$0.023 loss in 1H 2020)

We Think Shareholders Will Probably Be Generous With Polarean Imaging plc's (LON:POLX) CEO Compensation

Here's Why We're Watching Polarean Imaging's (LON:POLX) Cash Burn Situation

Full year 2020 earnings released: US$0.044 loss per share (vs US$0.057 loss in FY 2019)

Insider Buying: The Polarean Imaging plc (LON:POLX) Independent Chairman Just Bought 6.6% More Shares

Polarean Imaging (LON:POLX) Is In A Good Position To Deliver On Growth Plans

Polarean Imaging plc Announces the Appointment of Charles Fremont Osborne Jr. to the Board

Polarean Imaging (LON:POLX) Shareholders Have Enjoyed An Impressive 135% Share Price Gain

Should You Take Comfort From Insider Transactions At Polarean Imaging plc (LON:POLX)?

Polarean Imaging plc Announces FDA Acceptance for the Filing of New Drug Application

New 90-day high: UK£0.80

What Type Of Shareholders Own The Most Number of Polarean Imaging plc (LON:POLX) Shares?

New 90-day high: UK£0.80

Polarean Imaging plc Receives Research Unit Order for A 9820 Xenon Polariser System from the University of Texas MD Anderson Cancer Center

New 90-day high: UK£0.49

Polarean Imaging plc Announces Submission of New Drug Application

First half earnings released

Polarean Imaging plc Completes the Installation of its Latest Research Unit Order for A 9820 Xenon Polariser System

New 90-day high: UK£0.47

New 90-day high - UK£0.36

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş